Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis

Critical Reviews in Toxicology

Volumn 46, Issue 6, 2016, Pages 477-489

  Onakpoya, Igho J ^a   Heneghan, Carl J ^a   Aronson, Jeffrey K ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adverse reaction; interval; side effect; systematic review; worldwide recall

Indexed keywords

APROTININ; BENOXAPROFEN; CATECHIN; CENTOXIN; CERIVASTATIN; CHLORMEZANONE; CHLORPROGUANIL PLUS DAPSONE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DILEVALOL; DOMPERIDONE; FENCLOFENAC; FENFLURAMINE; GLAFENINE; GREPAFLOXACIN; HERBACEOUS AGENT; INDOPROFEN; ISOXICAM; LAROPIPRANT PLUS NICOTINIC ACID; LOPERAMIDE; MUZOLIMINE; NOMIFENSINE; OXYPHENBUTAZONE; PEMOLINE; PIRPROFEN; PRENYLAMINE; RICINOMACROGOL; ROFECOXIB; TRYPTOPHAN; UNINDEXED DRUG;

ADVERSE OUTCOME; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; DEATH; DRUG EFFECT; DRUG WITHDRAWAL; HUMAN; LIVER TOXICITY; NEUROTOXICITY; NONHUMAN; PARALYTIC ILEUS; REVIEW; SYSTEMATIC REVIEW; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FACTUAL DATABASE; META ANALYSIS; SUBSTANCE WITHDRAWAL SYNDROME;

DATABASES, FACTUAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84961233831     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.3109/10408444.2016.1149452     Document Type: Review

References (35)

1. A.Akhtar,, 2015. The flaws and human harms of animal experimentation. Cambridge quarterly of healthcare ethics, 24, 407–419.
2. Anonymous, 1984. Fenclofenac withdrawn. The lancet, 2, 56.
3. J.K.Aronson,, ed., 2015. Fenclofenac. Meyler’s side effects of drugs: the international encyclopedia of adverse drug reactions and interactions. 16th ed. The Netherlands: Elsevier.
4. J.K.Aronson, and R.E.Ferner,, 2010. Preventability of drug-related harms - part II: proposed criteria, based on frameworks that classify adverse drug reactions. Drug safety, 33, 995–1002.
5. N.A.Ashford,, 2004. Implementing the precautionary principle: incorporating science, technology, fairness, and accountability in environmental, health, and safety decisions. International journal of occupational medicine and environmental health, 17, 59–67.
6. N.D.Barnard, and S.R.Kaufman,, 1997. Animal research is wasteful and misleading. Scientific American, 276, 80–82.
7. M.B.Bracken,, 2009. Why animal studies are often poor predictors of human reactions to exposure. Journal of the royal society of medicine, 102, 120–122.
8. European Commission, 2009. A guideline on summary of product characteristics (SmPC). Available from: http://ec.europa.eu/health/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf [Accessed 15 September 2015].
9. European Medicines Agency, 2012. Standard operating procedure. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Standard_Operating_Procedure_-_SOP/2009/09/WC500003189.pdf [Accessed 15 September 2015].
10. R.C.Giles,, et al., 1978. Mammary nodules in beagle dogs administered investigational oral contraceptive steroids. Journal of the national cancer institute, 60, 1351–1364.
11. F.P.Gruber, and T.Hartung,, 2004. Alternatives to animal experimentation in basic research. Alternatives to animal experiments, 21, 3–31.
12. J.J.Guo,, et al., 2010. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group. Value health, 13, 657–666.
13. J.A.Hirst,, et al., 2014. The need for randomization in animal trials: an overview of systematic reviews. PLoS one, 9, e98856.
14. P.Jüni,, et al., 2004. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. The lancet, 364, 2021–2029.
15. S.Khangura,, et al., 2012. Evidence summaries: the evolution of a rapid review approach. Systematic reviews, 1, 10.
16. J.H.Kim, and A.R.Scialli,, 2011. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicological sciences, 122, 1–6.
17. A.Knight,, 2008. Systematic reviews of animal experiments demonstrate poor contributions toward human healthcare. Reviews on recent clinical trials, 3, 89–96.
18. R.P.Kwapien,, et al., 1980. Malignant mammary tumors in beagle dogs dosed with investigational oral contraceptive steroids. Journal of the national cancer institute, 65, 137–144.
19. Y.K.Loke,, et al., 2006. Case reports of suspected adverse drug reactions-systematic literature survey of follow-up. British medical journal, 332, 335–339.
20. K.F.Mueller,, et al., 2014. Dissemination bias in systematic reviews of animal research: a systematic review. PLoS one, 9, e116016
21. I.J.Onakpoya,, et al., 2015. Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis. BMC medicine, 13, 26.
22. I.J.Onakpoya,, et al., 2016. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC medicine, 14(1), 10. doi: 10.1186/s12916-016-0553-2.
23. OCEBM Levels of Evidence Working Group, 2011. The Oxford 2011 levels of evidence. Oxford Centre for Evidence-Based Medicine. Available from: http://www.cebm.net/index.aspx?o=5653 [Accessed 17 July 2015].
24. P.F.Ricci,, et al., 2004. Precautionary principles: a jurisdiction-free framework for decision-making under risk. Human & experimental toxicology, 23, 579–600.
25. J.Talbot, and P.Waller,, eds, 2004. Stephens’ detection of new adverse drug reactions. 5th ed. Chichester: John Wiley and Sons Ltd.
26. R.H.ter Meulen,, 2005. The ethical basis of the precautionary principle in health care decision making. Toxicology and applied pharmacology, 207, 663–667.
27. The Merck Index, 2013. Encyclopedia of chemicals, drugs, and biologicals. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc.
28. M.Tubiana,, 2000. Conclusions. The precautionary principle: its advantages and risks. Bulletin de l'Académie nationale de médecine, 184, 969–993.
29. United States Food and Drug Administration (FDA), 2013. Regulatory procedures manual – October 2013. Chapter 7. Recall procedures. Available from: http://www.fda.gov/downloads/ICECI/ComplianceManuals/RegulatoryProceduresManual/UCM074312.pdf [Accessed 15 September 2015].
30. United States Food and Drug Administration (FDA), 2014a. Inside clinical trials: testing medical products in people. Available from: http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143531.htm [Accessed 15 September 2015].
31. United States Food and Drug Administration (FDA), 2014b. Accelerated approval program. Available from: http://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm [Accessed 17 November 2015].
32. J.van Luijk,, et al., 2014. Systematic reviews of animal studies; missing link in translational research? PLoS one, 9, e89981.
33. William Andrew Publishing, 2007. Pharmaceutical manufacturing encyclopedia. 3rd ed. Norwich, NY: William Andrew Publishing.
34. Wingspread Conference on the Precautionary Principle, 1998. Available from: http://www.sehn.org/wing.html [Accessed 11 November 2015].
35. World Health Organization Collaborating Centre for Drug Statistics Methodology (WHO), 2008. Complete ATC/DDD Index. Available from: http://www.whocc.no/atcddd [Accessed 21 April 2013].